Home LiteratureArticle Details
PMID: 8784097 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?

The Journal of clinical endocrinology and metabolism ·Vol. 81 ·No. 9 ·1996-09-00 ·Pages 3360-5

Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL

Abstract

The ret/PTC oncogene is unique to papillary thyroid cancer. Three forms of this oncogene, formed by translocation of three different genes to the tyrosine kinase domain of the ret protooncogene, result in constitutive kinase activation. Correlation with clinical outcome is controversial; ret/PTC-1 has been suggested to predict aggressive behavior. There is no morphological description of ret/PTC-positive tumors. We analyzed 60 thyroid carcinomas for ret/PTC expression to determine correlation with clinical history, disease stage, or tumor morphology. Ribonucleic acid extracted from frozen tissue was reverse transcribed; PCR was performed to amplify ret/PTC-1, 2, and -3. The TPC-1 cell line was the positive control for ret/PTC-1. All tumors were characterized morphologically. Clinical data were collected. The 57 papillary and 3 follicular carcinomas were resected from 44 female patients and 15 males. The average age at diagnosis was 46.2 yr (range. 24-83 yr). Three patients had a history of neck irradiation. At diagnosis, 11 patients had extrathyroidal tumor extension, 20 had lymph node metastases, and 1 had lung metastasis. Thirteen patients had tall cell papillary carcinomas; 3 tumors had focal insular or anaplastic dedifferentiation. The average follow-up was 13.4 months, during which 4 patients had recurrent disease. No deaths occurred. One papillary carcinoma (1.7%) was positive for ret/PTC-1, none was positive for ret/PTC-2, and 2(3.4%) were positive for ret/PTC-3. Although all 3 patients who had tumors containing ret/PTC rearrangements were under the age of 45 yr (range, 26-44 yr) and had small tumors (< 1.2 cm), 2 of these 3 patients presented with lymph node metastases, and the third had lymphatic invasion. ret/PTC oncogene expression did not correlate with radiation history. In summary, ret/PTC oncogene rearrangements were found in 3 of 60 (5%) thyroid carcinomas and were not present in tumors with aggressive morphological features. However, we found ret/PTC rearrangements in young patients (< 45 yr of age) with small thyroid carcinomas showing a predisposition for lymphatic involvement, suggesting a possible role in the development of this subgroup of tumors.

MeSH Terms
Adult Aged Aged, 80 and over Base Sequence Drosophila Proteins Female Humans Male Middle Aged Molecular Sequence Data Neoplasm Metastasis/genetics Oncogene Proteins/genetics Oncogene Proteins, Fusion Oncogenes/genetics Polymerase Chain Reaction Protein-Tyrosine Kinases Proto-Oncogene Proteins/genetics Proto-Oncogene Proteins c-ret RNA-Directed DNA Polymerase Receptor Protein-Tyrosine Kinases/genetics Sequence Analysis Thyroid Neoplasms/genetics
Chemicals
Drosophila Proteins Oncogene Proteins Oncogene Proteins, Fusion Proto-Oncogene Proteins Protein-Tyrosine Kinases Proto-Oncogene Proteins c-ret RET protein, human Receptor Protein-Tyrosine Kinases Ret protein, Drosophila ret-PTC fusion oncoproteins, human RNA-Directed DNA Polymerase
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Sugg S L
Department of Surgery, University of Toronto, Ontario, Canada.
Zheng L
Rosen I B
Freeman J L
Ezzat S
Asa S L
Article Info
Journal
The Journal of clinical endocrinology and metabolism
Abbr.
J Clin Endocrinol Metab
ISSN
0021-972X
Published
1996-09-00
Pages
3360-5
Language
English
Region
United States
NLM ID
0375362
Subset
IM
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com